Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Lisa Carey
aTyr Pharma, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Atyr Investigative Site
Los Angeles, California, United States
Recruiting - Atyr Investigative Site
San Diego, California, United States
Recruiting - Atyr Investigative Site
Miami, Florida, United States
Recruiting - Atyr Investigative Site
Chicago, Illinois, United States
Recruiting - Atyr Investigative Site
Chicago, Illinois, United States
Recruiting - Atyr Investigative Site
Chicago, Illinois, United States
Recruiting - Atyr Investigative Site
New Orleans, Louisiana, United States
Recruiting - Atyr Investigative Site
New York, New York, United States
Recruiting - Atyr Investigative Site
Cleveland, Ohio, United States
Recruiting - Atyr Investigative Site
Oklahoma City, Oklahoma, United States
Recruiting - Atyr Investigative Site
Charleston, South Carolina, United States
Recruiting - Atyr Investigative Site
Dallas, Texas, United States
Recruiting - Atyr Investigative Site
Houston, Texas, United States
Recruiting - Atyr Investigative Site
Salt Lake City, Utah, United States
Recruiting - Atyr Investigative Site
Richmond, Virginia, United States
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 26 Oct 2023
- Primary completion
- 30 Apr 2026
- Completion
- 30 Apr 2026
- Last update posted
- 7 May 2025
- Registered enrollment
- 25
- Registry id
- NCT05892614
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.